Scientific Reports (Aug 2019)

Human metallo-β-lactamase enzymes degrade penicillin

  • Seydina M. Diene,
  • Lucile Pinault,
  • Vivek Keshri,
  • Nicholas Armstrong,
  • Saber Khelaifia,
  • Eric Chabrière,
  • Gustavo Caetano-Anolles,
  • Philippe Colson,
  • Bernard La Scola,
  • Jean-Marc Rolain,
  • Pierre Pontarotti,
  • Didier Raoult

DOI
https://doi.org/10.1038/s41598-019-48723-y
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Nonribosomal peptides are assemblages, including antibiotics, of canonical amino acids and other molecules. β-lactam antibiotics act on bacterial cell walls and can be cleaved by β-lactamases. β-lactamase activity in humans has been neglected, even though eighteen enzymes have already been annotated such in human genome. Their hydrolysis activities on antibiotics have not been previously investigated. Here, we report that human cells were able to digest penicillin and this activity was inhibited by β-lactamase inhibitor, i.e. sulbactam. Penicillin degradation in human cells was microbiologically demonstrated on Pneumococcus. We expressed a MBLAC2 human β-lactamase, known as an exosome biogenesis enzyme. It cleaved penicillin and was inhibited by sulbactam. Finally, β-lactamases are widely distributed, archaic, and have wide spectrum, including digesting anticancer and β-lactams, that can be then used as nutriments. The evidence of the other MBLAC2 role as a bona fide β-lactamase allows for reassessment of β-lactams and β-lactamases role in humans.